Daily Newsletter

23 November 2023

Daily Newsletter

23 November 2023

Memorial Hermann deploys Laudio’s AI tech to help frontline leaders

Laudio's platform automates repetitive tasks and provides daily recommendations to help frontline leaders.

November 22 2023

Memorial Hermann Health System, a non-profit health system in Houston, has deployed Laudio's AI Workflow Automation Platform to enhance efficiency and engagement among its frontline leaders.

Laudio's platform automates repetitive tasks and provides daily recommendations to help frontline leaders stay connected with their teams.

Memorial Hermann has initially rolled out the platform at Memorial Hermann Northeast Hospital, with plans for system-wide expansion.

Laudio CEO and co-founder Russ Richmond said: “Frontline leaders are keystone roles within health systems, but tedious tasks and siloed systems limit their ability to harness opportunities for proactive, personalised engagement with their teams and patients.

“Memorial Hermann shares our commitment to enhancing support for frontline leaders and we’re proud to forge a strategic relationship with them.”

The health system has also invested in Laudio, as part of Laudio's recent $13m Series B funding round.

Simultaneously, the platform has been introduced at various healthcare systems, including Northwell Health and Nebraska Medicine.

The investment is said to align with Memorial Hermann's focus on people-centred initiatives to address the challenges faced by frontline workers.

Laudio's platform has been adopted by nearly 20 health systems across the country to streamline workflows and improve leader efficiency.

Memorial Hermann SVP and chief nursing executive Bryan Sisk said: “By empowering frontline leaders to spend less time on administrative work, we’re giving them more time to support their teams and patients in meaningful ways.

“We’re excited to leverage this new platform to improve our team members’ daily lives and their overall satisfaction.”

Texas-based Memorial Hermann Health System is a Level I trauma centre with over 6,600 affiliated physicians and 33,000 employees.

It provides care across 250 care delivery sites.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close